Pharmaceuticals

Old Drugs Given New Life: Acura NanoMedicine Inc. Upgrades Existing Drugs Providing a More Efficient the Treatment for Cancer

TAIPEI, Dec. 13, 2021 /PRNewswire/ -- Taiwanese company Acura NanoMedicine Inc ( https://www.acura-nanomed.com/ ), an award-winning health tech and biomedicine company, announces a groundbreaking nanotech-based solution to reduce instances of drug resistance and giv...

2021-12-14 00:00 2462

CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting

SHANGHAI, Dec. 13, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announces that at the 2021 American Society of Hematology ("ASH") Annual ...

2021-12-13 20:00 6026

Cleverin, Top Made-in-Japan Airborne Disinfectant Brand by Taiko Pharmaceutical, Accelerating Its Business Expansion in Mexico through Acquisition of Its Mexican Distributor

OSAKA, Japan, Dec. 13, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced that it fully acquired Mexican distributor Torishi S.A. de C.V. inNovember 2021 in order to expand the infection control business. Taiko has worked with the excellen...

2021-12-13 14:00 3468

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN JOSE and SAN FRANCISCO and NANJING, China, Dec. 12, 2021 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative medicines and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-cla...

2021-12-13 12:14 2757

Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate Safety profile was favorable and consis...

2021-12-13 09:03 3605

Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other ma...

2021-12-13 08:00 4260

StemiRNA Therapeutics appoints Dr. Jack Hu as Chief Financial Officer

SHANGHAI and BOSTON, Dec. 12, 2021 /PRNewswire/ -- StemiRNA, a leader in research and development of mRNA therapeutics, welcomes Dr.Jack Hu as Chief Financial Officer. Dr. Hu brings nearly two decades of experience in healthcare investment research, financial management and corporate strategy. Dr...

2021-12-13 07:00 2414

Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2021-12-12 18:50 5138

Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

* TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate * Safety profile was favorable and ...

2021-12-12 09:00 6839

Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx

SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...

2021-12-10 15:15 5376

CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies

CASTRES, France, Dec. 10, 2021 /PRNewswire/ -- Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment or applying a dose escalation schedule of neratinib...

2021-12-10 15:11 3148

Research shows Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19

SHIJIAZHUANG, China, Dec. 10, 2021 /PRNewswire/ -- "Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19", claimed an article titled "Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Tr...

2021-12-10 12:49 4282

Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan

TAIPEI, Taiwan, Dec. 8, 2021 /PRNewswire/ -- Bobby Sheng, chairman of Bora Pharmaceuticals (6472.TWO), today announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum, whereby the two parties will jointly invest up toNT$3 billion (approx. US$108 millio...

2021-12-10 12:17 4198

I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma

SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at8:00 a.m. EST o...

2021-12-09 21:00 2342

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530),  South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...

2021-12-09 20:18 2823

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...

2021-12-09 20:00 3289

Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer

HELSINKI, Dec. 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onDecember 9th, 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as ...

2021-12-09 16:58 1627

Posters Highlighting clinical data of KN026 presented at SABCS 2021

SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that two posters highlighting data from two clinicalstudies of the anti-HER2 bispecific antibody KN026 were presented at the 44th San...

2021-12-09 12:20 2935

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

- Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population - In the overall p...

2021-12-09 08:38 3496

Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs

* Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders * Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development * Two Phase 1/2 clinical trials to launch shortly in Queens...

2021-12-09 07:35 3602
1 ... 314315316317318319320 ... 345

Week's Top Stories